Kim, T.; Hao, C.; Pan, M.; Ganjoo, K.N.; Bui, N.Q.
Gemcitabine Plus Docetaxel, Dacarbazine, Doxorubicin Combinations, or Doxorubicin Alone as First-Line Treatment for Advanced/Metastatic Leiomyosarcoma: A Retrospective Analysis at a Sarcoma Center. Diseases 2025, 13, 79.
https://doi.org/10.3390/diseases13030079
AMA Style
Kim T, Hao C, Pan M, Ganjoo KN, Bui NQ.
Gemcitabine Plus Docetaxel, Dacarbazine, Doxorubicin Combinations, or Doxorubicin Alone as First-Line Treatment for Advanced/Metastatic Leiomyosarcoma: A Retrospective Analysis at a Sarcoma Center. Diseases. 2025; 13(3):79.
https://doi.org/10.3390/diseases13030079
Chicago/Turabian Style
Kim, Ted, Clara Hao, Minggui Pan, Kristen N. Ganjoo, and Nam Q. Bui.
2025. "Gemcitabine Plus Docetaxel, Dacarbazine, Doxorubicin Combinations, or Doxorubicin Alone as First-Line Treatment for Advanced/Metastatic Leiomyosarcoma: A Retrospective Analysis at a Sarcoma Center" Diseases 13, no. 3: 79.
https://doi.org/10.3390/diseases13030079
APA Style
Kim, T., Hao, C., Pan, M., Ganjoo, K. N., & Bui, N. Q.
(2025). Gemcitabine Plus Docetaxel, Dacarbazine, Doxorubicin Combinations, or Doxorubicin Alone as First-Line Treatment for Advanced/Metastatic Leiomyosarcoma: A Retrospective Analysis at a Sarcoma Center. Diseases, 13(3), 79.
https://doi.org/10.3390/diseases13030079
